Close menu

March 30th, 2023 | 12:15 CEST

Saturn Oil + Gas, Bayer, Amazon - Big business on a growth path

  • Mining
  • Oil
  • Pharma
  • entertainment
Photo credits:

The oil industry is booming again: since Russia has been severely sanctioned, EU companies are fleeing to their international production sites to operate cost-efficiently. The winner in the energy poker is Saturn Oil & Gas. The Canadian company is now presenting its results for fiscal year 2022. What is clear is how hard the Company has worked on substance to grow steadily. Change is also felt at Bayer in the wake of the CEO change. Research in the field of women's health is discontinued, only one new blockbuster is still in the pipeline, but it is a big one. The fact that the stock market is associated with fear and greed is shown by the jump in AMC's share price. Just one piece of news from Amazon takeover rumors has investors jumping at the chance.

time to read: 4 minutes | Author: Juliane Zielonka
ISIN: Saturn Oil + Gas Inc. | CA80412L8832 , BAYER AG NA O.N. | DE000BAY0017 , AMAZON.COM INC. DL-_01 | US0231351067

Table of contents:

    John Jeffrey, CEO, Saturn Oil + Gas Inc.
    "[...] The Oxbow Asset now delivers a substantial free cash flow stream to internally fund our impactful drilling and workover programs. [...]" John Jeffrey, CEO, Saturn Oil + Gas Inc.

    Full interview


    Saturn Oil & Gas - FY 2022 financial results

    Sanctions against Russia are making it difficult for European companies, in particular, to supply their local production sites with cost-efficient energy. DAX corporations such as BASF, Bayer and Volkswagen are consequently increasing the output of their sites in non-European countries. Demand for oil and gas has never been as high as it is now.

    The Canadian company Saturn Oil & Gas convinces with results from the last fiscal year. In 2022, the Company's operational achievements are impressive, with a focus on optimizing existing assets to now taking steps toward growth. "Last year was the most active year for light oil development in Saturn's history. The Company drilled 57.5 horizontal wells targeting light oil with 100% success," commented Justin Kaufmann, Chief Development Officer.

    Average production increased 133% to 9,593 boe/d, compared to average production of 4,117 boe/d in 2021. Adjusted cash flow increased 335% to EUR 80.5 million, compared to EUR 18.5 million in 2021, resulting in an 89% increase in adjusted cash flow per share to EUR 1.81, compared to EUR 0.96 in 2021.

    On February 28, 2023, the Company completed the acquisition of Ridgeback Resources Inc, a private oil and gas producer focused on light oil in Saskatchewan and Alberta, Canada. The Ridgeback acquisition adds approximately 17,000 boe/d of current production (71% light oil and NGLs) and 670 net sections of land.

    "In addition to the recently completed Ridgeback acquisition, Saturn has made two additional acquisitions in our primary development area in West Central Saskatchewan. In addition to the high net light oil production acquired, the extensive land base gained from the acquisitions has been the focus of our drilling activity in 2022." For investors, the full results here are available for review. For those interested in meeting the management team in a live video presentation, please SAVE THE DATE for May 10, 2023, when VP Kevin Smith will speak about future plans and be available in a Q&A for all interested investors at 6 pm CET (12 pm EST, 12 pm HKT). Click here to go to pre-registration.

    Bayer - Moving away from women's health to neuroscience and oncology

    Structural changes are looming in the Bayer Group just before the new CEO Bill Anderson takes office. Bayer's pharmaceuticals unit, headed by Stefan Oelrich, is leaving women's health. A few years ago, that sounded quite different, marked by the acquisition of Schering AG, which became successful, especially with hormone preparations for contraception.

    "In research and subsequent clinical phases, we will no longer focus explicitly on women's health," Oelrich said. The Company is in the midst of clinical development of the non-hormonal menopause drug elinzanetant, opening up a potential global market for menopausal women experiencing menopause-related symptoms. In 2022, the global menopause products market was estimated to be worth EUR 14.8 billion. In 2023, this market is expected to grow to EUR 15.6 billion. Moving away from women's health signals investors to take a more solid stance and steer away from lawsuit traps that have so far cost the group billions.

    Future pharma pipeline focuses on drug discovery and development of therapeutics in neurology, oncology, cardiovascular disease, rare diseases and immunology. For a series of recent agreements aimed at becoming a major player in cell and gene therapy has caused neurology, rare diseases and immunology to take on an increasingly important role, according to Oelrich's statement.

    WallStreetBets - AMC soars on Amazon takeover rumors

    Shares of movie theatre operator AMC were up about 11% by Monday's close. Amazon founder Jeff Bezos is said to have instructed his investment advisors to explore takeover options for US cinema chain AMC. Thanks to the share price gain, the Company now has a market value of around EUR 2.2 billion. AMC became a popular stock among a community of non-institutional short-sellers on Reddit called r/wallstreetbets. This dedicated group of retail investors specializes in seeking out stocks with a high risk for short selling.

    Short-selling involves an investor borrowing an asset (e.g., stock) and agreeing to buy it back at a later date and return it to the original owner. Short-sellers bet on falling prices. Securities such as GameStop or AMC experienced huge price gains of well over 100% in a very short period of time due to the Reddit community. As one of the famous "meme" stocks, AMC was valued at more than EUR 21.2 billion at the peak of the Reddit-triggered price increase in June 2021. Thus, AMC came to be grossly overvalued despite a poor economy.

    Since the pandemic and the continued expansion of streaming offerings, movie theatre operators like AMC have found it difficult to attract sufficient audiences. High inflation and increased costs for everyday goods are also causing consumers to cut back, especially on leisure budgets. According to Refinitiv, AMC has a total long-term debt of EUR 4.8 billion.

    Canada's Saturn Oil & Gas stands out with a solid fiscal 2022. It has laid the foundation for solid growth in the years ahead. When Buffett increases his investments in oil companies, it is a sign for investors to take a closer look at this very industry. On the other hand, Bayer investors are looking with great hope to the coming change in leadership at the top of the Group. The major clean-up is beginning, and the focus is increasingly on growth markets such as neurology and oncology. Those who prefer to turn to lighter topics can look to AMC and the entertainment market, which Amazon serves with its Prime offering - maybe with classic movie theatres like in the times before streaming offers.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author

    Related comments:

    Commented by Juliane Zielonka on December 8th, 2023 | 07:20 CET

    Which stocks are leading the fight against cancer and chronic diseases? Defence Therapeutics, Merck and BioNTech

    • Biotechnology
    • Pharma

    The pharmaceutical industry is facing complex developments in the fight against cancer, with Defence Therapeutics making significant progress with the successful FDA filing for its drug for the targeted treatment of tumors. The growing market opportunities in oncology until 2032 underline the potential of this breakthrough. In contrast, Merck KGaA is experiencing a severe setback with an 11% share price decline following the failure of evobrutinib for the relief of MS in late-stage clinical trials. According to analysts, this also impacts the Company's valuation. Despite promising cancer-fighting approaches, BioNTech faces uncertainties due to a reduced revenue forecast for 2023 and an 'Underweight' rating from JP Morgan. Despite these challenges, the sector remains dynamic. Find out which shares could be worthwhile in the long term here.


    Commented by André Will-Laudien on December 7th, 2023 | 08:50 CET

    Snow chaos and climate madness, who is playing in the Premier League of the energy transition? Nel ASA, Power Nickel and Plug Power under the microscope

    • Mining
    • Nickel
    • BatteryMetals
    • renewableenergies
    • Energy

    Snow chaos and new record highs. While the DAX 40 demonstrates itself as the world's best blue-chip index, the German economy is currently navigating downward. It is not the earnings outlook that is presently driving share prices but the hope of lower interest rates. Meanwhile, the endless climate debates in Dubai continue. Among realists, however, there must be fears that the local oil lobby will not let a German know-it-all put a stop to the lavish margins with fossil fuels. There will, at least, be a friendly Arab nod to the 2050 climate goals and exclusive indulgence for the high-ranking German delegation. Whether this justifies federal expenditure of more than EUR 50 million is something we will leave uncommented. More important is a look at the top titles of the upcoming energy transition - where is the next 100 percenter lurking?


    Commented by Juliane Zielonka on December 7th, 2023 | 07:00 CET

    New developments in the healthcare market: Cardiol Therapeutics, Amazon and Bayer shares in focus

    • Biotechnology
    • Pharma
    • Healthcare

    Cardiol Therapeutics, a clinical-stage life sciences company focusing on therapies for heart inflammation, has secured a renowned clinic to advance its Phase II MAvERIC-Pilot study. This study, focused on combating recurrent pericarditis, promises to provide sound approaches to improve the quality of life of affected patients. Amazon has been dabbling in the healthcare sector since 2015 and is gradually conquering the telemedicine market. The path to telemedicine for Prime members, through the acquisition of companies such as "One Medical" and "PillPack", poses challenges. In contrast, Bayer is once again caught in the crossfire of legal disputes. The recent glyphosate trial loss before a jury in Philadelphia calls for a strategic realignment. At the same time, Bayer is attempting to provide new impetus in the area of women's health through a partnership in the field of hormonal contraception. Find out which development holds promise here.